145 related articles for article (PubMed ID: 30851629)
21. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
22. Advanced breast cancer updates on anastrozole versus tamoxifen.
Nabholtz JM;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):321-5. PubMed ID: 14623528
[TBL] [Abstract][Full Text] [Related]
23. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
24. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.
Johnson KE; Forward JA; Tippy MD; Ceglowski JR; El-Husayni S; Kulenthirarajan R; Machlus KR; Mayer EL; Italiano JE; Battinelli EM
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):664-674. PubMed ID: 28153880
[TBL] [Abstract][Full Text] [Related]
26. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Doggrell SA
Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
28. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Karnon J; Delea T; Barghout V
Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
[TBL] [Abstract][Full Text] [Related]
29. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
Eur J Cancer; 2000 Sep; 36 Suppl 4():S84-5. PubMed ID: 11056332
[TBL] [Abstract][Full Text] [Related]
30. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Bell R; Lewis J
Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
[TBL] [Abstract][Full Text] [Related]
31. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
32. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
33. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Boccardo F; Guglielmini P; Bordonaro R; Fini A; Massidda B; Porpiglia M; Roagna R; Serra P; Orzalesi L; Ucci G; Rubagotti A
Eur J Cancer; 2013 May; 49(7):1546-54. PubMed ID: 23415888
[TBL] [Abstract][Full Text] [Related]
34. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
35. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
36. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Dowsett M; Tobias JS; Howell A; Blackman GM; Welch H; King N; Ponzone R; von Euler M; Baum M
Br J Cancer; 1999 Jan; 79(2):311-5. PubMed ID: 9888474
[TBL] [Abstract][Full Text] [Related]
37. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions.
Miller ME; Dores GM; Thorpe SL; Akerley WL
Thromb Res; 1994 Jun; 74(6):577-94. PubMed ID: 8091401
[TBL] [Abstract][Full Text] [Related]
38. Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells.
Pather K; Augustine TN
J Thromb Thrombolysis; 2022 Oct; 54(3):401-410. PubMed ID: 35932382
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen-induced thrombocytopenia.
Yao JC; Thomakos N; McLaughlin P; Buchholz TA; Kudelka AP
Am J Clin Oncol; 1999 Oct; 22(5):529-32. PubMed ID: 10521073
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Valenzano Menada M; Costantini S; Moioli M; Bogliolo S; Papadia A; Ferrero S; Dugnani MC
Breast; 2008 Dec; 17(6):631-6. PubMed ID: 18606545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
